View this email in your browser ([link removed])
[link removed]
[link removed] [link removed]
BREAKING NEWS ALERT
Biogen Inc.’s experimental Alzheimer’s disease therapy failed to gain support from a panel of US Food and Drug Administration advisers on Friday, putting the drug at a crossroads as the agency weighs approval.

The outside experts voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show Biogen’s drug works. The vote contradicts a report FDA reviewers prepared ahead of the meeting that supported the efficacy of the drug, called aducanumab, though there was dissent in the agency.

Read the full story on BostonGlobe.com ([link removed]) .
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])

[link removed]
[link removed] [link removed]

============================================================
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2020 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)